<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557713</url>
  </required_header>
  <id_info>
    <org_study_id>AVACROSS</org_study_id>
    <nct_id>NCT00557713</nct_id>
  </id_info>
  <brief_title>XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma</brief_title>
  <official_title>Treatment of Induction With XELOX-Bevacizumab in Locally Advanced Rectal Adenocarcinoma: Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pathological complete response rate of addition
      of bevacizumab to induction therapy (xelox) and concomitant treatment
      (capecitabine+radiotherapy), followed by surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>after concomitant CT-RT treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Resection (R0) Rate</measure>
    <time_frame>after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>from complete response to relapse or disease-related death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Failure Treatment</measure>
    <time_frame>from first treatment dose to drop out of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastatic or Local Recurrence</measure>
    <time_frame>during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Evaluation</measure>
    <time_frame>during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Morbility</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Rectal Neoplasms</condition>
  <condition>Locally Advanced Rectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)
-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))
-Surgery (6-8 weeks after last bevacizumab dose)
-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)
-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))
-Surgery (6-8 weeks after last bevacizumab dose)
-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from patients who are able to understand the study request

          -  Histologically confirmed diagnosis of locally advanced rectal adenocarcinoma; ≤12 cm
             from the anal margin; T3, operable T4 or TxN+

          -  Karnofsky PS Index ≥ 70%

          -  Life expectancy &gt; 6 months

          -  Adequate bone marrow, liver and renal function: ANC ≥ 1.5 x 10e9/l; Platelets ≥ 100 x
             10e9/l; Hb ≥ 9g/dl; INR ≤ 1.5; Bilirubin ≤ 1.5 x ULN; ALT and/or AST ≤ 2.5 x ULN or ≤
             5 x ULN (in case of hepatic metastasis); Alkaline phosphatase ≤ 2.5 x ULN or ≤ 5 x ULN
             (in case of hepatic metastasis) or ≤ 10 x ULN (in case of bone metastasis); Creatinine
             clearance (Cockcroft-Gault) ≥ 30 ml/min or seric creatinine ≤ 1.5 x ULN

        Exclusion Criteria:

          -  Distant metastases; previous neoplasm during last 5 years or previous infiltrating
             neoplasm; previous treatment with radiotherapy or study drugs; recruited for other
             clinical trial in 4 weeks before study entry

          -  Surgery, open biopsy or traumatic injury in 4 weeks before study entry; fine-needle
             aspiration in 7 days before study entry; major surgery planned during study

          -  Previous heart disease or uncontrolled hypertension, previous hemorrhagic diathesis or
             coagulopathy; full-dose oral or parenteral anticoagulant or thrombolytic agent
             (low-dose warfarin is allowed, INR ≤ 1.5); chronic use of high-dose aspirin
             (&lt;325mg/day) or non-steroidal anti-inflammatory treatment

          -  No integrity of the upper gastrointestinal tract, malabsorption syndrome or unable to
             take oral drugs

          -  Pregnant or lactating patients; SNC disease; allogeneic transplant with
             immunosuppressive drugs; bone fracture not healed, wound or severe ulcers;
             uncontrolled intercurrent severe infections; previous related-fluoropyrimide SAEs or
             DPD deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miquel Nogué, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ACROSS</name>
      <address>
        <city>Barcelona</city>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Portal, MD</last_name>
      <email>inmaportal@teleline.es</email>
    </contact>
    <investigator>
      <last_name>Miquel Nogué, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernardo Queralt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carles Pericay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ferran Losa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José María Roca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pilar Vicente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Rolfo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inmaculada Guasch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Arriví, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Cabrera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María José Safont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaspar Esquerdo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Ruiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonieta Salud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.acrosscancer.org</url>
    <description>across</description>
  </link>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>November 13, 2007</last_update_submitted>
  <last_update_submitted_qc>November 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

